Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies

This publication has 45 references indexed in Scilit:

• The role of Fas ligand in immune privilege
  Nature Reviews Molecular Cell Biology, 2001
• Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells
  Nature Medicine, 1998
• Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)
  Science, 1998
• Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
  Proceedings of the National Academy of Sciences, 1997
• Is cancer dangerous to the immune system?
  Seminars in Immunology, 1996
• Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
  Science, 1995
• Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
  The Journal of Experimental Medicine, 1995
• Interaction of peptides derived from the Fas ligand with the Fyn-SH3 domain
  FEBS Letters, 1995
• A role for CD95 ligand in preventing graft rejection
  Nature, 1995
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
  Proceedings of the National Academy of Sciences, 1993